Shire PLC (NASDAQ:SHPG) – Research analysts at SunTrust Banks reduced their FY2018 earnings estimates for shares of Shire PLC in a research note issued to investors on Monday. SunTrust Banks analyst J. Boris now expects that the biopharmaceutical company will post earnings per share of $16.32 for the year, down from their prior forecast of $16.37. SunTrust Banks also issued estimates for Shire PLC’s FY2020 earnings at $23.82 EPS and FY2021 earnings at $27.19 EPS.
A number of other analysts have also weighed in on SHPG. BidaskClub upgraded shares of Shire PLC from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. Cantor Fitzgerald set a $222.00 price target on shares of Shire PLC and gave the company a “buy” rating in a research note on Saturday, July 1st. HSBC Holdings plc upgraded shares of Shire PLC from a “reduce” rating to a “hold” rating in a research note on Thursday, July 6th. ValuEngine upgraded shares of Shire PLC from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 price target on shares of Shire PLC in a research note on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and thirteen have given a buy rating to the company’s stock. Shire PLC currently has an average rating of “Buy” and an average target price of $220.91.
ILLEGAL ACTIVITY WARNING: “Analysts Issue Forecasts for Shire PLC’s FY2018 Earnings (SHPG)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/10/27/analysts-issue-forecasts-for-shire-plcs-fy2018-earnings-shpg.html.
Shire PLC (NASDAQ:SHPG) traded down 2.97% during mid-day trading on Wednesday, reaching $147.53. 1,322,582 shares of the company were exchanged. Shire PLC has a 1-year low of $139.36 and a 1-year high of $192.64.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%.
The business also recently declared a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be issued a dividend of $0.1527 per share. This represents a dividend yield of 0.21%. The ex-dividend date of this dividend is Thursday, September 7th. Shire PLC’s dividend payout ratio is presently 41.07%.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Afam Capital Inc. lifted its holdings in shares of Shire PLC by 8.8% during the second quarter. Afam Capital Inc. now owns 29,879 shares of the biopharmaceutical company’s stock worth $4,938,000 after purchasing an additional 2,410 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Shire PLC during the second quarter worth $406,000. Verition Fund Management LLC lifted its holdings in shares of Shire PLC by 18.9% during the second quarter. Verition Fund Management LLC now owns 2,967 shares of the biopharmaceutical company’s stock worth $490,000 after purchasing an additional 472 shares during the period. Sterling Capital Management LLC acquired a new stake in shares of Shire PLC during the second quarter worth $299,000. Finally, Delphi Management Inc. MA lifted its holdings in shares of Shire PLC by 10.5% during the second quarter. Delphi Management Inc. MA now owns 13,350 shares of the biopharmaceutical company’s stock worth $2,206,000 after purchasing an additional 1,270 shares during the period. 19.24% of the stock is owned by hedge funds and other institutional investors.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.